Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through acquisition, GSK to integrate Elsie’s oligonucleotide discovery, synthesis, and delivery technologies to enhance GSK’s broad oligonucleotide pipeline for difficult-to-treat diseases.
Lead Product(s): Oligonucleotide-based Therapy
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition June 06, 2024
Details:
Through a license agreement, GSK will have the option to utilize Elsie’s discovery platform and P(V) chemistry technologies for its research in oligonucleotide drug discovery.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 14, 2024
Details:
The collaboration aims to advance the discovery and development of Elsie’s innovative oligonucleotide discovery platform for finding novel oligonucleotides by combining GSK's extensive expertise in DNA encoded library technologies with Elsie's drug discovery platform.
Lead Product(s): Oligonucleotide Drug
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 10, 2023